Abstract:The growing number of chemicals in the current consumer and industrial markets presents a major challenge for regulatory programs faced with the need to assess the potential risks they pose to human and ecological health. The increasing demand for hazard and risk assessment of chemicals currently exceeds the capacity to produce the toxicity data necessary for regulatory decision making, and the applied data is commonly generated using traditional approaches with animal models that have limited context in terms of human relevance. This scenario provides the opportunity to implement novel, more efficient strategies for risk assessment purposes. This study aims to increase confidence in the implementation of new approach methods in a risk assessment context by using a parallel analysis to identify data gaps in current experimental designs, reveal the limitations of common approaches deriving transcriptomic points of departure, and demonstrate the strengths in using high-throughput transcriptomics (HTTr) to derive practical endpoints. A uniform workflow was applied across six curated gene expression datasets from concentration-response studies containing 117 diverse chemicals, three cell types, and a range of exposure durations, to determine tPODs based on gene expression profiles. After benchmark concentration modeling, a range of approaches was used to determine consistent and reliable tPODs. High-throughput toxicokinetics were employed to translate in vitro tPODs (µM) to human-relevant administered equivalent doses (AEDs, mg/kg-bw/day). The tPODs from most chemicals had AEDs that were lower (i.e., more conservative) than apical PODs in the US EPA CompTox chemical dashboard, suggesting in vitro tPODs would be protective of potential effects on human health. An assessment of multiple data points for single chemicals revealed that longer exposure duration and varied cell culture systems (e.g., 3D vs. 2D) lead to a decreased tPOD value that indicated increased chemical potency. Seven chemicals were flagged as outliers when comparing the ratio of tPOD to traditional POD, thus indicating they require further assessment to better understand their hazard potential. Our findings build confidence in the use of tPODs but also reveal data gaps that must be addressed prior to their adoption to support risk assessment applications.

Mapping Interindividual Variability of Toxicodynamics Using High-Throughput Transcriptomics and Primary Human Hepatocytes from Fifty Donors

Transcriptomic mapping of the inter-individual variability of cellular stress response activation in primary human hepatocytes

Characterization of Conserved Toxicogenomic Responses in Chemically Exposed Hepatocytes across Species and Platforms

Classification of Hepatotoxicants Using HepG2 Cells: A Proof of Principle Study

Population-Based in Vitro Hazard and Concentration–Response Assessment of Chemicals: the 1000 Genomes High-Throughput Screening Study

Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing

Qualitative and Quantitative Concentration-Response Modelling of Gene Co-expression Networks to Unlock Hepatotoxic Mechanisms for Next Generation Chemical Safety Assessment

Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity

Quantitative High-Throughput Screening for Chemical Toxicity in a Population-Based in Vitro Model.

Probing Liver Injuries Induced by Thioacetamide in Human In Vitro Pooled Hepatocyte Experiments

Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology

HiPSC-Derived Hepatocyte-like Cells Can Be Used as a Model for Transcriptomics-Based Study of Chemical Toxicity

Development and validation of a high-throughput transcriptomic biomarker to address 21st century genetic toxicology needs

A Pipeline for High-Throughput Concentration Response Modeling of Gene Expression for Toxicogenomics

Toxicogenomics Approaches to Address Toxicity and Carcinogenicity in the Liver

In Pursuit of Effective Toxicogenomics

A network-based transcriptomic landscape of HepG2 cells uncovering causal gene-cytotoxicity interactions underlying drug-induced liver injury

A human population-based organotypic in vitro model for cardiotoxicity screening

Chemical target and pathway toxicity mechanisms defined in primary human cell systems

From vision toward best practices: Evaluating in vitro transcriptomic points of departure for application in risk assessment using a uniform workflow